Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) shares gapped down before the market opened on Wednesday after JPMorgan Chase & Co. lowered their price target on the stock from $174.00 to $165.00. The stock had previously closed at $134.68, but opened at $117.02. JPMorgan Chase & Co. currently has an overweight rating on the stock. Ascendis Pharma A/S shares last traded at $120.57, with a volume of 483,117 shares.
Other equities analysts have also recently issued research reports about the company. TD Cowen dropped their target price on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research report on Wednesday. StockNews.com cut Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. Bank of America raised their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday. Wells Fargo & Company lowered their price target on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $188.09.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth $78,719,000. Price T Rowe Associates Inc. MD grew its stake in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock valued at $191,346,000 after buying an additional 254,749 shares during the period. Acadian Asset Management LLC lifted its position in Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares in the last quarter. Finally, Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after acquiring an additional 229,995 shares in the last quarter.
Ascendis Pharma A/S Stock Performance
The stock has a fifty day simple moving average of $135.06 and a two-hundred day simple moving average of $138.60. The stock has a market cap of $6.96 billion, a PE ratio of -12.43 and a beta of 0.63.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.